Czech
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Strana 1 z 351 Výsledek
Methods for determining cancer resistance to histone deacetylase inhibitors
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
BACKGROUND OF THE INVENTION
The highly heterogeneous response of the same type of cancer (e.g., colon cancer) to a given anti-cancer compound in different patients is one of the most vexing and tragic problems of modern medicine. It is widely thought that human genetic and epigenetic diversity
Methods for determining cancer resistance to histone deacetylase inhibitors
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
BACKGROUND OF THE INVENTION
The highly heterogeneous response of the same type of cancer (e.g., colon cancer) to a given anti-cancer compound in different patients is one of the most vexing and tragic problems of modern medicine. It is widely thought that human genetic and epigenetic diversity
Compositions for treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
FIELD OF INVENTION
This invention relates to the treatment of patients with cancer, particularly cancer in advanced stages through combination therapies comprising the use of hyperbaric oxygen with histone deacetylase inhibitors with and without glycolytic therapies.
BACKGROUND OF THE INVENTION
In
Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
FIELD OF INVENTION
This invention relates to the treatment of patients with cancer, particularly cancer in advanced stages through combination therapies comprising the use of hyperbaric oxygen with histone deacetylase inhibitors with and without glycolytic therapies.
BACKGROUND OF THE INVENTION
In
Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
FIELD OF INVENTION
This invention relates to the treatment of patients with cancer, particularly cancer in advanced stages through combination therapies comprising the use of hyperbaric oxygen with histone deacetylase inhibitors with and without glycolytic therapies.
BACKGROUND OF THE INVENTION
In
Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a tumour antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal.
Histone deacetylase (HDAC) inhibitors for the treatment of cancer
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
FIELD OF INVENTION
The present invention relates to methods for treating cancer. In one respect, the present invention relates to a method of treating cancer (e.g., solid tumour cancer, e.g., rectal cancer, colon cancer, ovarian cancer; hematological cancer, e.g., multiple myeloma, leukemia,
Histone deacetylase (HDAC) inhibitors for the treatment of cancer
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
FIELD OF INVENTION
The present invention relates to methods for treating cancer. In one respect, the present invention relates to a method of treating cancer (e.g., solid tumour cancer, e.g., rectal cancer, colon cancer, ovarian cancer; hematological cancer, e.g., multiple myeloma, leukemia,
Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
RELATED APPLICATION
This application is a national stage filing under 35 U.S.C. 371 of International Application No. PCT/GB2006/004215 filed on 10 Nov. 2006, which is related to U.S. provisional patent application 60/735,701 filed 10 Nov. 2005, the contents of which are incorporated herein by
Compound and analogues for tracing histone acetylation inhibitors PET imaging for diagnosis and treatment of tumors
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
BACKGROUND OF THE INVENTION
Field of the Invention
The present invention relates to PET imaging compounds and analogues for tracing histone deacetylases inhibitor (HDACi) for tumor diagnosis and therapy, and more particularly to compounds of nuclear medicine imaging tracer which is capable of
Use of histone acetyltransferase inhibitors as novel anti-cancer therapies
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
BACKGROUND OF THE INVENTION
The reversible acetylation of histones and other proteins is a major mechanism for cellular regulation. Acetylation on protein lysine residues is catalyzed by histone acetyltransferases (HATs) and acetyl-Lys cleavage is performed by histone deacetylases (HDACs). These
Pharmaceutical combination comprising a class III receptor tyrosine kinase inhibitor and the alkylating histone-deacetylase inhibitor fusion molecule EDO-S101 together with its use in the treatment of cancer
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a U.S. national stage filing under 35 U.S.C. .sctn. 371(c), of International Application No. PCT/EP2015/061569, filed on May 26, 2015, which claims foreign priority of U.K. Patent Application No. 1409488.2, filed on May 28, 2014. The entire
Treatment of cancer of the brain using histone deacetylase inhibitors
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
BACKGROUND OF THE INVENTION
Compounds which inhibit histone deacetylase (HDACs) have been shown to cause growth arrest, differentiation and/or apoptosis of many different types of tumor cell in vitro and in vivo. HDACs catalyze the removal of the acetyl group from the lysine residues in the
Histone deacetylase (HDAC) inhibitors targeting prostate tumors and methods of making and using thereof
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
FIELD OF THE INVENTION
The present invention generally relates to histone deacetylase (HDAC) inhibitors that target prostate tumor. More particularly, the invention describes a series of arylhydantoin derived HDAC inhibitors that target androgen positive prostate tumors through their interaction
Methods for treating solid tumor cancers using a histone deacetylase inhibitor and an I.kappa.B kinase inhibitor
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
FIELD OF THE INVENTION
The present invention discloses a method for treating a solid tumor cancer comprising administering to a subject in need thereof a therapeutically effective amount of a histone deacetylase (HDAC) inhibitor and a therapeutically effective amount of an I.kappa.B kinase (IKK)
Nejúplnější databáze léčivých bylin podložená vědou
- Funguje v 55 jazycích
- Bylinné léky podporované vědou
- Rozpoznávání bylin podle obrázku
- Interaktivní mapa GPS - označte byliny na místě (již brzy)
- Přečtěte si vědecké publikace související s vaším hledáním
- Hledejte léčivé byliny podle jejich účinků
- Uspořádejte své zájmy a držte krok s novinkami, klinickými testy a patenty
Zadejte symptom nebo chorobu a přečtěte si o bylinách, které by vám mohly pomoci, napište bylinu a podívejte se na nemoci a příznaky, proti kterým se používá.
* Všechny informace vycházejí z publikovaného vědeckého výzkumu
